A phase 1 study showed that pulse/continuous-dose erlotinib (1200 mg on days 1–2 and 50 mg on days 3–7 weekly) produced a 75% CNS response rate in EGFR mutated lung cancer patients with untreated brain metastases [23]. The gene discussed is EGFR; the disease is lung carcinoma.